Ohio State Navbar

Clinical Trials



If you would like more information or are interested in referring a patient to one of these trials, click on the PI's name to generate a contact email or call The James Line at 1-800-293-5066.  To search all cancer clinical trials available at Ohio State, visit cancer.osu.edu.

Featured Trials
  • Phase I, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884), and to Estimate the Maximum Tolerated Dose in Subjects With Advanced or Refractory Cancer
    (OSU-15281) Robert Wesolowski, MD
Recently Opened Trials


  • PALLAS: Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy vs. Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer
    (OSU-16010) Raquel Reinbolt, MD


  • Phase I/II, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies
    (OSU-15241) Kristen Ciombor, MD
  • Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
    (ALLIANCE-A021501) Terence Williams, MD, PhD


  • Randomized Phase II Trial of Cisplatin/Gemcitabine With or Without VX-970 in Metastatic Urothelial Carcinoma
    (OSU-17029) Amir Mortazavi, MD

Head and Neck

  • Open-Label, Multicenter Phase I/II Study of Mogamulizumab in Combination With Nivolumab in Subjects With Locally Advanced or Metastatic Solid Tumors
    (OSU-16147) Maura Gillison, MD, PhD


  • Randomized, Controlled, Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
    (OSU-16073) Harrison Howard, MD


  • Phase Ib Study of AZD9291 in Combination With Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor
    (OSU-16155) Erin Bertino, MD
Immune Therapy Trials


  • Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Patients With Her2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane-Based Therapy
    (OSU-16193) Robert Wesolowski, MD


  • Phase I, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
    (OSU-15169) Kristen Ciombor, MD
  • Phase II Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors
    (OSU-14006) Kristen Ciombor, MD
  • Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
    (OSU-15298) Richard Goldberg, MD
  • Phase I, Open-Label, Multiple-Ascending-Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
    (OSU-13257) John Hays, MD, PhD


  • NEW: Phase I, Multiple-Dose, Dose-Escalation Trial of Pt2385 Tablets, a HIF-2alpha Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma (OSU-16236) J. Paul Monk, III, MD
  • Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti−Pd-L1 Antibody) vs. Observation as Adjuvant Therapy in Patients With Pd-L1−Selected, High-Risk Muscle-Invasive Bladder Cancer After Cystectomy
    (OSU-16078) Amir Mortazavi, MD
  • Phase I Study of (Cabozantinib) Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
    (OSU-15150) Amir Mortazavi, MD
  • Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab vs. Placebo After First-line Chemotherapy in Patients With Metastatic Urothelial Cancer
    (OSU-16133) Amir Mortazavi, MD
  • Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)
    (OSU-14248) Thomas Olencki, DO
  • Phase III, Multinational, Randomized, Open-label, Parallel-Arm Study of Avelumab (Msb0010718c) in Combination With Axitinib (Inlyta®) vs. Sunitinib (Sutent®) Monotherapy in the First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
    (OSU-15292) Thomas Olencki, DO


  • Phase I/II Study of Chemo-Immunotherapy With Toll-Like Receptor 8 Agonist Motolimod (VTX-2337) and Anti-PD-L1 Antibody MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated
    (OSU-15125) David O’Malley, MD

  • Phase I/IIa Dose-Escalation and Cohort Expansion Study for Safety, Tolerability and Efficacy of BMS-986156 Administered Alone and in Combination With Nivolumab (BMS-936558, anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors
    (OSU-16195) David O’Malley, MD

Head and Neck

  • Phase I and Expansion Cohort Study Of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, And Mk-3475 (Pembrolizumab) In High-Risk Head And Neck Squamous Cell Carcinoma (HNSCC)
    (NRG-HN003) Dukagjin Blakaj, MD, PhD


  • Randomized, Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
    (ECOG-EA6134) Joanne Jeter, MD
  • Phase I/II Trial of Pembrolizumab in Combination With Imatinib in Patients With Locally Advanced or Metastatic Melanoma With c-KIT Mutation or Amplification
    (OSU-15280) Joanne Jeter, MD
  • Phase II and Pilot Trial of PD-1 Blockade With MK-3475 (Pembrolizumab) in Patients With Resectable or Unsectable Desmoplastic Melanoma (DM)
    (SWOG-S1512) Kari Kendra, MD, PhD


  • Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
    OSU-15244 (Manisha Shah, MD)


  • Phase Ib Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan-High Solid Tumors
    (OSU-15219) Erin Bertino, MD

  • Phase I/Ib, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab Therapy in Patients With Selected Incurable Cancers
    (OSU-16051) Erin Bertino, MD

  • Phase II Fast Real-Time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)
    (OSU-16136) Kai He, MD, PhD

  • Phase II, Dose-Escalation and Cohort-Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
    (OSU-16120) Kai He, MD, PhD

  • Phase I, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel/Carboplatin in Stage IIIb/IV Non-Small Cell Lung Cancer or Nab- Paclitaxel in Recurrent Metastatic Breast Cancer
    (OSU -14250) Greg Otterson, MD
  • Randomized, Multicenter, Double-Blind, Phase III Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-Based First-Line Chemotherapy
    (OSU-15171) Greg Otterson, MD
  • Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition With Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients With Chemotherapy-Naive Stage IV Non-Small Cell Lung Cancer
    (OSU-16074) Greg Otterson, MD
  • Open-Label, Multicenter, Phase I/II Study of Mogamulizumab in Combination With Nivolumab in Subjects With Locally Advanced or Metastatic Solid Tumors
    (OSU-16147) Greg Otterson, MD
Featured Trial From Nationwide Children's Hospital

Nationwide Children's HospitalPhase I Multicenter, Open-Label, Dose De-Escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec (TVEC) in Pediatric Subjects With Advanced Non-Central Nervous System Tumors That are Amenable to Direct Injection

PI: Keri Streby, MD at keri.streby@nationwidechildrens.org Sponsor: Amgen  NCT: 02756845




Updated: 3/27/17



© 2016 The Ohio State University Comprehensive Cancer Center –
James Cancer Hospital and Solove Research Institute
460 W. 10th Avenue
Columbus, Ohio 43210


Jamesline Blog  Facebook  Twitter  LinkedIn  Google+  Instagram  YouTube  Pinterest  Cancer Connect